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1 To whom correspondence should be addressed several observations argue against the ability of mutant p53
Email: mikhailb@box-m.nih.gov to change the conformation of wild-type p53 because mutant Overexpression of ectopic mutant p53 represses wild-type p53 proteins having a wild-type conformation are still able to p53-stimulated transcription, known as a dominant exert dominant negative effects (16). Furthermore, mutant p53 negative effect. On the other hand, overexpression of wildcan inhibit transcriptional activity of wild-type p53 without type p53 can repress transcription stimulated by several heterooligomerization (17). transcription factors, including hypoxia-inducible factor-1
When overexpressed wild-type p53 blocks transcription (HIF-1). Using a panel of well-characterized Arg175 p53 from numerous promoters lacking p53-binding sites (18) (19) (20) (21) (22) (23) (24) , mutants we found that only mutants (Tyr175, Trp175, including transcription that is stimulated by hypoxia inducible Asp175 and Phe175) which have completely lost their factor-1 (HIF-1). Under hypoxic conditions HIF-1 activates ability to transactivate repress wild-type p53-stimulated transcription of genes encoding glucose transporters, glycolytic Bax, p21 and PG13 promoter constructs. In contrast, enzymes and vascular endothelial growth factor in order to Asn175, Gln175, Leu175 and Pro175 mutants which parfacilitate metabolic adaptation to hypoxia (25, 26) . HIF-1 is tially retained transactivating functions did not exert domessential for tumor vascularization and development (27) . As inant negative effects against PG13 and p21 promoter previously shown for wild-type p53 (22, 28) , we found that constructs. However, these latter mutants failed to activate some mutant p53s can inhibit HIF-1-stimulated transcription.
Bax and, instead, exerted a dominant negative effect on a
Transrepression by p53 may be a result of competition with Bax-Luc promoter construct. We conclude that a dominant other transcription factors for co-activators. In this scenario negative effect is promoter selective as a consequence of p53s would most strongly compete with themselves (e.g. wildselective loss of transactivating function. Albeit less potent type with mutant) for any co-activators. This predicts that than wild-type p53, all Arg175 p53 mutants retained partial mutant p53 that has lost its ability to transactivate but is able to ability to repress HIF-1-stimulated transcription. We protransrepress will inhibit wild-type p53-stimulated transcription. pose that transrepression and the dominant negative effect
Here we have used a previously well-characterized panel of have similar mechanisms and may involve competition codon 175 (Arg) p53 mutants (21, 29) . Codon 175 in p53 is one of the hot-spots for mutation in human cancer, because with transcription factors (wild-type p53, HIF-1, etc.) for this residue plays an important role in maintaining the structure cofactors such as p300. Thus, a p53(22/23) mutant, which of the DNA-binding domain (30, 31) . We compared the ability is deficient in p300 binding, did not exert dominant negative of these mutants to activate p53-responsive promoters (transeffects. Like transrepression, the dominant negative effect activation) with their ability to inhibit p53-dependent transcriprequired overexpression of mutant p53 and, therefore, is tion in cells with wild-type p53 (dominant negative effect) not dominant. In the presence of a wild-type p53 allele, and their ability to inhibit HIF-1-stimulated transcription (translevels of endogenous mutant p53 protein were low in repression). We demonstrate that the loss of transactivating heterozygous cells. Endogenous mutant p53 became overfunction by mutant p53 coupled with a certain ability to expressed only after loss of the second p53 allele. Therefore, transrepress is sufficient and required to exert a negative effect. endogenous mutant p53s are unable to display a dominant
We demonstrate that the dominant negative effect is promoter negative effect. This explains why loss of the second p53 selective, a phenomenon which was previously unrecognized allele is required to eliminate p53 functions in cancer cells.
but can be explained if one proposes that transrepression (inhibition of a heterologous promoter) and dominant negative activity (inhibition of a homologous promoter) have similar Introduction mechanisms. Since the loss of transactivating function is Wild-type p53 is a transcription factor that binds to specific promoter specific, the dominant negative effect is also prosequences in DNA and transactivates numerous genes, includmoter specific. ing p21, Bax and Mdm-2 (1-5). Mutations in the p53 tumor Materials and methods suppressor are the most common alterations in human tumors. Mutations in p53 can result in loss of its functions and in (p53-null), were obtained from ATCC and incubated in RPMI-1640 medium (NCI, NIH, Bethesda, MD) and was described previously (34, 35) . The pCMVβ.HA-HIF-1α expression plasmid was obtained from D.Livingston and 10% fetal bovine serum. A2780 (1A9) is a single cell clone of the human ovarian carcinoma cell line A2780. Epothilone-resistant subclones, designated (Dana Farber Cancer Institute, Boston, MA). PcDNA3.1 was obtained from Invitrogen (Carlsbad, CA). pCMV-Luc was prepared by subcloning the CMV A4 and A8, were isolated by exposure to 6 ng/ml epothilone A. PTX22, a paclitaxel-resistant clone, was initially isolated as individual clones in a single promoter (digested with NheI and HindIII from pcDNA3.1) in the PGL3B vector (Invitrogen). step selection, by exposing 1A9 cells to 5 ng/ml paclitaxel in the presence of 5 µg/ml verapamil, a Pgp antagonist. After initial expansion in 5 ng/ml Transient transfection assay paclitaxel, the concentration of paclitaxel in the medium was gradually Aliquots of 50 000 cells were plated in 24-well plates (Costar, Acton, MA). increased to 15 ng/ml. Adriamycin was obtained from Sigma and dissolved
The next day the cells were transfected with plasmids in the presence of in DMSO as a 2 mg/ml stock solution. Epothilone A was obtained from Dr Frank Lee (Bristol Myers, Princeton, NJ) and paclitaxel was from Bristol-Myers.
p53 expression vectors and p53-responsive and HIF-1-responsive promoters
Ad-p53, a wild-type p53-expressing replication-deficient adenovirus, was obtained from Dr B.Vogelstein (Johns Hopkins University). Viral titer was determined as previously described (32) . Multiplicity of infection is defined as the ratio of total number of viruses used in a particular infection to the number of cancer cells to be infected (i.e. number of viruses per cell). BaxLuc, a Bax promoter-luciferase construct was previously described (21) . WWP-Luc, a p21 promoter-luciferase construct, and PG13-Luc, containing a generic p53 response element, were obtained from Dr B.Vogelstein. The control luciferase plasmid, pGL2-Control, driven by the SV40 promoter and enhancer sequences, was purchased from Promega (Madison, WI). PCMVgalactosidase was purchased from Clontech (Palo Alto, CA). Arg175 mutants were described previously (21, 29) . The p53 double point mutant p53(22/23) was described previously (33).
HRE-Luc, a HIF-responsive construct that encompasses the hypoxiaresponsive element of the iNOS promoter, was provided by Dr G.Melillo 
Lipofectamine (Gibco BRL, Gaithersburg, MD). If indicated cells were
The dominant negative effect is promoter specific transfected with TransFast Transfection Reagent (Promega) according to the To evaluate whether loss of transactivation function and the manufacturer's recommendations. After 3-6 h incubation with the plasmiddominant negative effect are promoter selective we performed lipid suspension in OptiMeM medium the medium was changed and cells were grown for an additional 16-36 h, if indicated under hypoxic conditions experiments using a Bax promoter construct which differs (1% O 2 ), then cells were lysed and analyzed for luciferase activity. In some from other p53-responsive promoters in two ways. First, as experiments, when anoxia-mimicking conditions instead of hypoxia were shown in Figure 1 , endogenous wild-type p53 was not sufficient used, cells were incubated with 160 µM desferrioxamine (DFX) as previously to activate Bax-Luc, which was activated by overexpressed described (36) .
wild-type p53. Second, it is not activated by some p53 mutants
Immunoblot analysis
which otherwise activate p21-Luc (21, 39) . Pro175 and Asn175
Cells were lysed in TNES buffer (50 mM Tris-HCl, pH 7.5, 2 mM EDTA, possessed full ability to transactivate PG13-Luc and p21-Luc 100 mM NaCl, 1 mM sodium orthovanadate, 1% NP40) containing protease (Figure 2 and data not shown) but they did not inhibit inhibitors (20 µg/ml aprotinin, 20 µg/ml leupeptin, 1 mM phenylmethylsulfonyl wild-type p53-stimulated PG13-Luc or p21-Luc (no dominant fluoride). Proteins were resolved by 8% SDS-PAGE for the detection of p53 or by 12.5% SDS-PAGE for the detection of p21, as previously described negative effect). However, Pro175 and Asn175 mutants, like (37) . Immunoblotting for p53 and p21 was performed using antibodies from to inhibit Bax-Luc (dominant negative effect) was examined, by p53
like Phe175, both Pro175 and Asn175 were able to inhibit We used p53-inducible constructs with the p21 WAF1/CIP1 (p21-wild-type p53-stimulated Bax-Luc ( Figure 3B ). Consistent Luc) or Bax (Bax-Luc) promoters and also a construct with a with this, Phe175, which was least able to transactivate Baxp53 consensus binding site repeated 13 times (PG13-Luc) Luc ( Figure 3A ), had the most potent dominant negative effect (3,38). MCF-7 cells which have endogenous wild-type p53 ( Figure 3B ). Thus, loss of transactivation function was coupled express PG13-Luc and p21-Luc at high levels, which therefore with the emergence of dominant negative effects. cannot be significantly further induced by exogenous wildDominant negative mutants can repress HIF-1-stimulated trantype p53. However, MCF-7 cells express Bax-Luc at low scription levels (Figure 1 ). Co-transfection with wild-type p53 stimulated Wild-type p53 can transrepress several cellular and viral Bax-Luc, demonstrating that while basal levels of wild-type promoters, including those with a HIF-1-binding site. As p53 are sufficient to transactivate p21-Luc and PG13-Luc, shown in Figure 1 , dominant negative Phe175 was able to higher levels are required to activate the Bax promoter contransrepress HIF-1-stimulated transcription. We next investistruct. In contrast, co-transfection with mutant p53 (Phe175) gated other p53 mutants. All mutants were able to transrepress inhibited both PG13-Luc and p21-Luc. This inhibition of p53 HRE-Luc transcription (Figure 4 ). Wild-type p53 and Cys175 transcription by mutant p53 is referred to as a dominant were the most potent repressors, with Gln175 the least potent. negative effect. Importantly, both wild-type p53 and Phe175
Transcriptionally inactive and dominant negative Tyr175, inhibited HIF-1-stimulated transcription (HRE-Luc). Phe175
Trp175 and Asp175 possessed intermediate activity. Similar did not stimulate any of the p53-responsive constructs results were obtained in all three cell lines examined, MCF- (Figure 1) . 7, PC3M and SKBr3, indicating that this effect was independent Loss of transactivating function correlates with a dominant of the endogenous p53 status. negative effect
Comparison of transrepression and dominant negative effects As shown above, the dominant negative effect of Phe175 was of mutant p53 associated with loss of its transactivating function, but their
We next compared the ability of wild-type p53 and transcripdominant negative abilities have never been tested. To further tionally inactive p53 mutants to transrepress HRE-Luc under examine the relationship of these two properties we compared normoxic (low basal HIF-1 activity) versus hypoxic conditions the dominant negative effects (Figure 2A ) and transactivating (high HIF-1 activity). Trp175 and other p53s were able to function ( Figure 2B Figure 5A ). The observation that HIF-1 2A). These and only these mutants had lost their transactivating could partially overcome p53-mediated transrepression was function ( Figure 2B) . We plotted the ability of mutant p53s to extended by performing similar experiments using DFX to transactivate PG13-Luc in PC3M versus their abilities to exert chemically induce endogenous HIF-1 protein (36). a dominant negative effect. Mutants lacking transactivation Furthermore, just as transrepression of HRE-Luc by p53 showed the highest dominant negative effects. Therefore, the could be partially abrogated by overexpression of HIF-1 dominant negative effect and loss of transactivation function (Figure 5A ), the dominant-negative effect of mutant p53 (Trp175) could be dampened by overexpression of wild-type were correlated ( Figure 2C) . Indeed, the extent of dominance is determined by the excess of mutant p53. Therefore, when SKBr3 cells with endogenous mutant p53 were transfected with wild-type p53 a 60-to 70-fold induction of expression of PG13 and Bax promoter constructs was observed ( Figure 6A ). Furthermore, endogenous p21 protein was dramatically induced by wild-type p53 and Pro175 in SKBr3 cells ( Figure 6B ). Since the transfection efficiency of SKBr3 cells did not exceed 10%, transfected p53s cannot be seen against the background of mutant endogenous p53. We next tested p53(22/23), a p53 double point mutant at residues 22 and 23 in the N-terminal domain, which is required for binding p300/CBP transcriptional co-activators (33,40). Both HIF-1α and p53 bind to p300 and p300 is required for the transcription functions of both HIF-1α and p53 (40-44). Therefore, the p53(22/23) mutant did not inhibit HIF-1-dependent transcription (22) , did not activate transcription and did not induce p21 protein ( Figure 6B ). Importantly, despite loss of transactivating functions, this mutant p53 did not exert a dominant negative effect ( Figure 6C ). Thus, the 22/23 mutant lacks both dominant negative and transre- high basal levels of p53 protein and therefore no further p53 induction following DNA damage.
Using either PG13-Luc ( Figure 7A ) or p21-Luc (data not p53 ( Figure 5B ). For example, the dominant negative effect of Trp175 was partially abolished by exogenous wild-type p53 shown) we found high levels of wild-type p53 activity in both heterozygous clones. As expected, p53-responsive plasmids or when endogenous wild-type p53 was induced by adriamycin, a DNA-damaging drug ( Figure 5B) .
were not expressed in clone PTX22 ( Figure 7A ), which lacks and transcription factor. In addition, p53 can repress transcription from several viral and cellular promoters, a property designated transrepression (18, 19, 47, 48) . This effect does not a wild-type p53 allele (46) . Furthermore, as in the parental cells, basal levels of p53 proteins were low in heterozygous require sequence-specific DNA (22, 42, 49) . For example, p53 represses the activity of HIF-1. Higher levels of p53 are clones ( Figure 7B ). Following DNA damage (ϩ adriamycin) induction of p53 was observed in both heterozygous clones required to inhibit HIF-1-stimulated transcription than to stimulate p53-dependent transcription (22,50,51).When highly overand parental cells. In contrast, the PTX22 clone lacking a wild-type p53 allele expressed high basal levels of mutant p53 expressed, p53 inhibits transcription in a less selective manner.
(a dominant negative effect). In contrast, the 'conformational model' (in which mutant p53 drives wild-type p53 into the mutant conformation) predicts a dominant negative effect nonselective for any particular promoter. Our findings are in agreement with the recent demonstration that p53 mutants can possess selective dominant negative effects on apoptosis but not growth arrest due to differential repression of Bax and p21 (55) . Furthermore, the fact that transactivation by mutant p53 may depend on cellular context may explain the observation that dominant negative effects are cell type dependent (56). Dominant negative mutants are the most common found in human cancers (57). We suggest that this reflects loss of transcriptional activity of tumor-derived p53. This explains why selection for transcriptionally inactive p53 mutants yielded transdominant mutants, even though transdominance was not a requirement for mutant isolation (58) . We conclude that a dominant negative effect is a consequence of loss of transactivating function. Finally, endogenous mutant p53 cannot efficiently repress endogenous wild-type p53 activity. As a result, loss of the second p53 allele is optimal since wildtype p53 function cannot be efficiently repressed; in the end, the easiest competitor is no competitor. 
